Genzyme to purchase rest of IG Laboratories
This article was originally published in Clinica
Genzyme's takeover of IG Laboratories has been approved by IG Labs' independent shareholders some seven months after Genzyme first proposed to buy the remaining shares in a stock swap (see Clinica No 642, p 14). Genzyme already owns around 70% of IG Labs whose shareholders will receive 0.1201 Genzyme General Division stock or around $7 for each IG Labs share held.
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.